154 related articles for article (PubMed ID: 38273367)
1. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components.
Li R; Qiu J; Li Z; Li H; Tang Z; Yu W; Tian H; Sun Z
World J Surg Oncol; 2024 Jan; 22(1):32. PubMed ID: 38273367
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
[TBL] [Abstract][Full Text] [Related]
4. Micropapillary Predominant Lung Adenocarcinoma in Stage IA Benefits from Adjuvant Chemotherapy.
Wang C; Yang J; Lu M
Ann Surg Oncol; 2020 Jun; 27(6):2051-2060. PubMed ID: 31848813
[TBL] [Abstract][Full Text] [Related]
5. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
[TBL] [Abstract][Full Text] [Related]
6. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
Zhang H; Sun FH; Chen ZC; Wang Q
Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):580-586. PubMed ID: 35658346
[No Abstract] [Full Text] [Related]
7. Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma?
Wang Y; Song W; Wang X; Che G
Pathol Res Pract; 2023 Feb; 242():154314. PubMed ID: 36706587
[TBL] [Abstract][Full Text] [Related]
8. A prognostic nomogram based on a new classification of combined micropapillary and solid components for stage IA invasive lung adenocarcinoma.
Huang W; Zhang H; Zhang Z; Zhang B; Sun X; Huo Y; Feng Y; Tian P; Mo H; Wang C
J Surg Oncol; 2022 Mar; 125(4):796-808. PubMed ID: 34862621
[TBL] [Abstract][Full Text] [Related]
9. [Association between the presence of solid or micropapillary components and survival outcome in stage ⅠA lung adenocarcinoma cases: a retrospective cohort study].
Jin KQ; Shen YR; Wu YM; Dai J; Liu XG; Li JQ; Chen LS; Jiang GN
Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):587-592. PubMed ID: 35658347
[No Abstract] [Full Text] [Related]
10. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.
Luo J; Huang Q; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Wang Y; Zheng J; Wu H; Xia W; Chen H
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2031-40. PubMed ID: 27379889
[TBL] [Abstract][Full Text] [Related]
11. Micropapillary or solid component predicts worse prognosis in pathological IA stage lung adenocarcinoma: A meta-analysis.
Wang Y; Hu J; Sun Y; Lu Y
Medicine (Baltimore); 2023 Dec; 102(49):e36503. PubMed ID: 38065873
[TBL] [Abstract][Full Text] [Related]
12. Value of adjuvant chemotherapy for patients with pT2N0M0 non-small cell lung cancer receiving radical resection.
Chen S; Yang S; Zhao Y; Zhang Y; Huang Q; Wu H; Hu H; Sun Y; Zhang Y; Xiang J; Ye T; Chen H
Thorac Cancer; 2024 Jan; 15(3):258-265. PubMed ID: 38098268
[TBL] [Abstract][Full Text] [Related]
13. [Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].
Shen L; Chen Y; Yun T; Guo J; Liu X; Zhang T; Liang C; Liu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):989-997. PubMed ID: 38862458
[TBL] [Abstract][Full Text] [Related]
14. High-risk characteristics of pathological stage I lung adenocarcinoma after resection: patients for whom adjuvant chemotherapy should be performed.
Wu LL; Jiang WM; Qian JY; Tian JY; Li ZX; Li K; Ma GW; Xie D; Chen C
Heliyon; 2023 Dec; 9(12):e23207. PubMed ID: 38144332
[TBL] [Abstract][Full Text] [Related]
15. [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].
Shen C; Fang W
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):593-600. PubMed ID: 36002196
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences.
Xu F; Chen HC; Xu H; Li J; Hao X; Xing P; Ying J; Wang Y
Thorac Cancer; 2022 Nov; 13(22):3105-3113. PubMed ID: 36104006
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Recurrence of Solid and Micropapillary Subtypes in Lung Adenocarcinoma.
Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
Oncology; 2024; 102(4):366-373. PubMed ID: 37899040
[TBL] [Abstract][Full Text] [Related]
18. Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis.
Wang W; Hu Z; Zhao J; Huang Y; Rao S; Yang J; Xiao S; Cao R; Ye L
J Cardiothorac Surg; 2020 Jun; 15(1):154. PubMed ID: 32600473
[TBL] [Abstract][Full Text] [Related]
19. A Nomogram Based on Consolidation Tumor Ratio Combined with Solid or Micropapillary Patterns for Postoperative Recurrence in Pathological Stage IA Lung Adenocarcinoma.
Zhang L; Liu J; Yang D; Ni Z; Lu X; Liu Y; Liu Z; Wang H; Feng M; Zhang Y
Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510119
[TBL] [Abstract][Full Text] [Related]
20. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
